Design Therapeutics, Inc.

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutic drugs for the treatment of genetic diseases. The company utilizes its proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidate targets Friedreich Ataxia, a progressive multi-system disease affecting neurological, cardiac, and metabolic functions. The company also has a portfolio addressing Myotonic Dystrophy Type-1, a neuromuscular disease; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease; and Huntington's Disease, a neurodegenerative disorder. Design Therapeutics is headquartered in Carlsbad, California and was incorporated in 2017.

Design Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol DSGN. The company's shares are traded in US Dollars (USD), as it is headquartered in the United States and operates primarily in the US market. The NasdaqGS is a major US stock exchange known for listing many biotechnology and technology companies, providing liquidity and visibility for investors.

Design Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing small molecule drugs for genetic diseases. Biotechnology companies like Design Therapeutics use biological processes and molecular biology to create therapies, often targeting rare or inherited conditions. The company's work in nucleotide repeat expansion diseases places it at the forefront of precision medicine for genetic disorders.

Design Therapeutics is headquartered in Carlsbad, California, United States. The company primarily serves the US market, as indicated by its US region classification. Its research and development activities are centered in the US, and it focuses on genetic diseases that affect populations worldwide, but its operations and regulatory filings are US-based. The company was incorporated in 2017 and has since been advancing its pipeline of therapies for inherited conditions.

Design Therapeutics' portfolio includes several product candidates targeting genetic diseases caused by nucleotide repeat expansion. Its lead candidate is for Friedreich Ataxia, a monogenic, autosomal recessive disease affecting mitochondrial function and causing neurological, cardiac, and metabolic issues. Other candidates include treatments for Myotonic Dystrophy Type-1, a dominantly-inherited neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease leading to corneal degeneration and vision loss; and Huntington's Disease, a dominantly-inherited neurodegenerative disorder characterized by movement, cognitive, and psychiatric problems. All candidates are developed using the company's GeneTAC platform.